These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 23176613)

  • 1. Assessing tumor heterogeneity and emergence mutations using next-generation sequencing for overcoming cancer drugs resistance.
    Roukos D; Batsis C; Baltogiannis G
    Expert Rev Anticancer Ther; 2012 Oct; 12(10):1245-8. PubMed ID: 23176613
    [No Abstract]   [Full Text] [Related]  

  • 2. Targeted therapy: overcoming drug resistance with clinical cancer genome.
    Ziogas DE; Katsios CS; Tzaphlidou M; Roukos DH
    Expert Rev Anticancer Ther; 2012 Jul; 12(7):861-4. PubMed ID: 22845399
    [No Abstract]   [Full Text] [Related]  

  • 3. Tumor complexity prompts caution about sequencing.
    Beckman M
    J Natl Cancer Inst; 2006 Dec; 98(24):1758-9. PubMed ID: 17179472
    [No Abstract]   [Full Text] [Related]  

  • 4. Disrupting cancer cells' biocircuits with interactome-based drugs: is 'clinical' innovation realistic?
    Roukos DH
    Expert Rev Proteomics; 2012 Aug; 9(4):349-53. PubMed ID: 22967071
    [No Abstract]   [Full Text] [Related]  

  • 5. How next-generation sequencing could change cancer care.
    O'Hanlon LH
    J Natl Cancer Inst; 2013 Jun; 105(12):836-8. PubMed ID: 23733908
    [No Abstract]   [Full Text] [Related]  

  • 6. Overcoming multidrug resistance in cancer: 35 years after the discovery of ABCB1.
    Gillet JP; Gottesman MM
    Drug Resist Updat; 2012; 15(1-2):2-4. PubMed ID: 22465109
    [No Abstract]   [Full Text] [Related]  

  • 7. Human DNA topoisomerase II: biochemistry and role in chemotherapy resistance (review).
    Withoff S; De Jong S; De Vries EG; Mulder NH
    Anticancer Res; 1996; 16(4A):1867-80. PubMed ID: 8712715
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical perspectives on the use of platinum compounds in cancer chemotherapy.
    Farrell NP
    Semin Oncol; 2004 Dec; 31(6 Suppl 14):1-9. PubMed ID: 15726528
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Overcoming of multidrug resistance by a newly synthesized quinoline compound, MS-209].
    Naito M; Nakanishi O; Tsuruo T
    Nihon Rinsho; 1997 May; 55(5):1122-7. PubMed ID: 9155163
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutant p53: the loaded gun.
    Selivanova G
    Curr Opin Investig Drugs; 2001 Aug; 2(8):1136-41. PubMed ID: 11892926
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical implications of tumor-cell heterogeneity.
    Schnipper L
    N Engl J Med; 1986 May; 314(22):1423-31. PubMed ID: 3517651
    [No Abstract]   [Full Text] [Related]  

  • 12. Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance.
    Shapira A; Livney YD; Broxterman HJ; Assaraf YG
    Drug Resist Updat; 2011 Jun; 14(3):150-63. PubMed ID: 21330184
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epigenetic mechanisms in tumorigenesis, tumor cell heterogeneity and drug resistance.
    Wilting RH; Dannenberg JH
    Drug Resist Updat; 2012; 15(1-2):21-38. PubMed ID: 22356866
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cancer and natural selection.
    Fillon M
    J Natl Cancer Inst; 2012 Dec; 104(23):1773-4. PubMed ID: 23213180
    [No Abstract]   [Full Text] [Related]  

  • 15. Contribution of somatic mutations in the mitochondrial genome to the development of cancer and tolerance against anticancer drugs.
    Ohta S
    Oncogene; 2006 Aug; 25(34):4768-76. PubMed ID: 16892089
    [TBL] [Abstract][Full Text] [Related]  

  • 16. On or off target: mutations, models, and predictions.
    Garraway LA; Hahn WC
    Sci Transl Med; 2010 Jun; 2(35):35ps28. PubMed ID: 20538617
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Crossroad between linear and nonlinear transcription concepts in the discovery of next-generation sequencing systems-based anticancer therapies.
    Roukos DH
    Drug Discov Today; 2016 Apr; 21(4):663-73. PubMed ID: 26912452
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor cell drug resistance and its reversal.
    Mansouri A; Henle KJ; Nagle WA; Moss AJ
    SAAS Bull Biochem Biotechnol; 1990 Jan; 3():91-6. PubMed ID: 1366508
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Problems in oncologic pharmacology].
    Filov VA; Gershanovich ML; Akimov MA; Akimov AA
    Vopr Onkol; 1998; 44(6):651-61. PubMed ID: 10087958
    [No Abstract]   [Full Text] [Related]  

  • 20. [Cancer genome analysis through next-generation sequencing].
    Aburatani H
    Gan To Kagaku Ryoho; 2011 Jan; 38(1):1-6. PubMed ID: 21368453
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.